The IASLC continues to disseminate this information and to recommend optimal molecular testing strategies
for lung cancer patients in collaboration with CAP / AMP.
That leaves Merck largely free of competitors in the near - term in its quest to become a go - to, first - line
option for lung cancer patients in combination with chemotherapy (Merck recently surprised investors with an early FDA filing for that combination).
If hypofractionated radiation with curative intent can reduce the treatment
time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»
Researchers at Moffitt Cancer Center and Tianjin Medical University Cancer Institute and Hospital in China have discovered a gene expression signature that may lead to new immune
therapies for lung cancer patients.
With the recent announcement that a first - line immunotherapy trial for non-small cell lung cancer (NSCLC) is positive for survival improvement, I can see the standard of care
for lung cancer patients radically changing over the next few years.
And it's exciting to be leading on the research to test a new potential drug which we hope will one day help increase the survival
rate for lung cancer patients.»
«We urgently need new
treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.